|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Polyethylene glycol rinse solution:An effective way to prevent ischemia-reperfusion injury显示文摘AIM:To test whether a new rinse solution containing polyethylene glycol 35(PEG-35)could prevent ischemia-reperfusion injury(IRI)in liver grafts.METHODS:Sprague-Dawley rat livers were stored in University of Wisconsin preservation solution and then washed with different rinse solutions(Ringer’s lactate solution and a new rinse solution enriched with PEG-35 at either 1 or 5 g/L)before ex vivo perfusion with Krebs-Heinseleit buffer solution.We assessed the following:liver injury(transaminase levels),mitochondrial damage(glutamate dehydrogenase activity),liver function(bile output and vascular resistance),oxidative stress(malondialdehyde),nitric oxide,liver autophagy(Beclin-1 and LCB3)and cytoskeleton integrity(filament and globular actin fraction);as well as levels of metalloproteinases(MMP2 and MMP9),adenosine monophosphate-activated protein kinase(AMPK),heat shock protein 70(HSP70)and heme oxygenase 1(HO-1).RESULTS:When we used the PEG-35 rinse solution,reduced hepatic injury and improved liver function were noted after reperfusion.The PEG-35 rinse solution prevented oxidative stress,mitochondrial damage,and liver autophagy.Further,it increased the expression of cytoprotective heat shock proteins such as HO-1 and HSP70,activated AMPK,and contributed to the restoration of cytoskeleton integrity after IRI.CONCLUSION:Using the rinse solution containing PEG-35 was effective for decreasing liver graft vulnerability to IRI. | Mohamed Amine Zaouali Mohamed Bejaoui Maria Calvo Emma Folch-Puy Eirini Pantazi Gianfranco Pasut Antoni Rimola Hassen Ben Abdennebi René Adam Joan Roselló-Catafau | 2014 | World Journal of Gastroenterology2014，20，43： | 6 |
| 2 | Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injury显示文摘Liver ischemia-reperfusion injury(IRI) is an inherent feature of liver surgery and liver transplantation in which damage to a hypoxic organ(ischemia) is exacerbated following the return of oxygen delivery(reperfusion). IRI is a major cause of primary nonfunction after transplantation and may lead to graft rejection, regardless of immunological considerations. The immediate response involves the disruption of cellular mitochondrial oxidative phosphorylation and the accumulation of metabolic intermediates during the ischemic period, and oxidative stress during blood flow restoration. Moreover, a complex cascade of inflammatory mediators is generated during reperfusion, contributing to the extension of the damage and finally to organ failure. A variety of pharmacological interventions(antioxidants, anticytokines, etc.) have been proposed to alleviate graft injury but their usefulness is limited by the local and specific action of the drugs and by their potential undesirable toxic effects. Polyethylene glycols(PEGs), which are non-toxic water-soluble compounds approved by the FDA, have been widely used as a vehicle or a base in food, cosmetics and pharmaceuticals, and also as adjuvants for ameliorating drug pharmacokinetics. Some PEGs are also currently used as additives in organ preservation solutions prior to transplantation in order to limit the damage associated with cold ischemia reperfusion. More recently, the administration of PEGs of different molecular weights by intravenous injection has emerged as a new therapeutic tool to protect liver grafts from IRI. In this review, we summarize the current knowledge concerning the use of PEGs as a useful target for limiting liver IRI. | Gianfranco Pasut Arnau Panisello Emma Folch-Puy Alexandre Lopez Carlos Castro-Benítez Maria Calvo Teresa Carbonell Agustín García-Gil RenéAdam Joan Roselló-Catafau | 2016 | World Journal of Gastroenterology2016，22，28： | 3 |
| 3 | State of the art in PEGylation: The great versatility achieved after forty years of research显示文摘 | Gianfranco Pasut Francesco M. Veronese | 2011 | Journal of Controlled Release2011，，2： | 2 |
| 4 | Relevance of folic acid/ polymer ratio in targeted PEG-epirubicin conjugates显示文摘 | Canal F Vicent MJ Pasut G | 2010 | Journal of Controlled Release2010，146，3： | 1 |
| 5 | PEGylation, successful approach to drug delivery显示文摘 | Veronese F M Pasut G | 2005 | Drug Discovery Today2005，10，21： | 1 |
| 6 | Anti-cancer PEG-enzymes: 30 years old, but still a current approach 显示文摘 | Pasut G Sergi M Veronese FM | 2008 | Adv Drug Deliv Rev2008，60，1： | 1 |
| 7 | Anti-cancer PEG-enzymes:30 years old, but still a current approach显示文摘 | Pasut G Sergi M Veronese FM | 2008 | Adv Drug Deliv Rev2008，60，1： | 1 |
| 8 | Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines显示文摘One of the main goals of vaccine research is the development of adjuvants that can enhance immune responses and are both safe and biocompatible.We explored the application of the natural polymer hyaluronan(HA)as a promising immunological adjuvant for protein-based vaccines.Chemical conjugation of HA to antigens strongly increased their immunogenicity,reduced booster requirements,and allowed antigen dose sparing.HA-based bioconjugates stimulated robust and long-lasting humoral responses without the addition of other immunostimulatory compounds and proved highly efficient when compared to other adjuvants.Due to its intrinsic biocompatibility,HA allowed the exploitation of different injection routes and did not induce inflammation at the inoculation site.This polymer promoted rapid translocation of the antigen to draining lymph nodes,thus facilitating encounters with antigen-presenting cells.Overall,HA can be regarded as an effective and biocompatible adjuvant to be exploited for the design of a wide variety of vaccines. | Anna Dalla Pietà Debora Carpanese Antonella Grigoletto Anna Tosi Silvia Dalla Santa Gabriel Kristian Pedersen Dennis Christensen Laura Meléndez-Alafort Vito Barbieri Paola De Benedictis Gianfranco Pasut Isabella Monia Montagner Antonio Rosato | 2021 | Cellular & Molecular Immunology2021，18，5： | 1 |
| 9 | State of the art in PEGylation:the greatversatility achieved after forty years of research显示文摘 | Pasut G Veronese FM | 2012 | J Control Release2012，，2： | 1 |
| 10 | Isolation of muscle stem cells by fluorescence activated cell sorting cytometry 显示文摘 | Pasut A Oleynik P Rudnieki MA | 2012 | Methods Mol Biol2012，798，1： | 1 |
| 11 | PEG - Ara - C conjugates for con- trolled release显示文摘 | Schiavon O Pasut G Moro S | 2004 | European Journal of Medicinal Chemistry2004，39，2： | 1 |
| 12 | PEG-Ara-C conjugates for controlled release 显示文摘 | SCHIAVON O PASUT G MORO S | 2004 | Eur J Med Chem2004，39，： | 1 |
| 13 | PEGylation, successful approach to drug delivery 显示文摘 | Yeionses F M Pasut G | 2005 | Drug D iscov Today2005，10，21： | 1 |
| 14 | PEGylation: Posttranslational bioengi- neering of protein biotherapeutics 显示文摘 | Veronese F M Pasut G | 2008 | Drug Discov TodayTechnol2008，5，23： | 1 |
| 15 | PEGylation for improving the effectiveness of therapeutic biomolecules 显示文摘 | Pasut G Veronese F M | 2009 | Drugs Today (Barc)2009，45，9： | 1 |
| 16 | Polymer-drug conjugation,recent achieve-ments and general strategies显示文摘 | Pasut G Veronese F | 2007 | Prog Polym Sci2007，32，8： | 1 |
| 17 | Comfort under personally controlled air movement in warm and humid environments显示文摘 | Yongchao Zhai Hui Zhang Yufeng Zhang Wilmer Pasut Edward Arens Qinglin Meng | 2013 | Building and Environment2013，，： | 1 |
| 18 | PEG conjugates in clinical development or use as anticancer agents: An overview显示文摘 | Gianfranco Pasut Francesco M. Veronese | 2009 | Advanced Drug Delivery Reviews2009，，13： | 1 |
| 19 | PEGylation for improving theeffectiveness of therapeutic biomolecules 显示文摘 | PASUT G VERONESE F M | 2009 | Drugs Today(Bare)2009，45，9： | 1 |
| 20 | Antitumoral activity ofPEG-gemcitabine prodrugs targeted by folic acid显示文摘 | Pasut G Canal F Dalla Via L | 2008 | J Con-trolled Rel2008，127，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员